Compounder Fund: Portfolio Update (August 2022) - 31 Aug 2022
Jeremy and I intend to share frequent but non-scheduled updates on how Compounder Fund’s portfolio looks like. The last time we shared an update on this was for Compounder Fund’s portfolio as of 10 July 2022.
In it, I shared all 50 holdings in the fund’s portfolio. As of the date of this update (31 August 2022), we’ve completely exited Teladoc and bought one new stock: Medpace. We used the cash that we got from the full sale of Teladoc, and partial sales of the fund’s stakes in Tencent and Sea, to invest in Medpace. Our detailed investment thesis on Medpace can be found here. We’ll explain in detail our reasons for selling Teladoc in the coming months in Compounder Fund’s website.
Here’s how Compounder Fund’s portfolio looks like as of 29 August 2022:
We’re sharing all this information with the public and with the fund’s investors for two reasons. First, we believe deeply in investor education and want Compounder Fund’s return and actions to be a source for people to learn about investing. Second, we believe that this transparency will help investors of Compounder Fund develop comfort with our investing process over time, which is great; in turn, this will also free us from the time-consuming activity of dealing with questions on how we invest, and thus give us more to invest better for our investors.
And here’s an important disclaimer: None of the information or analysis presented is intended to form the basis for any offer or recommendation; they are merely our thoughts that we want to share. Holdings are subject to change at any time.
